Journal List > J Menopausal Med > v.22(2) > 1092769

TOOLS
Engin-Üstün, Çağlayan, Göçmen, and Polat: Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels
Original Article

Journal of Menopausal Medicine 2016; 22(2): 76-79.

Published online: 30 August 2016

DOI: https://doi.org/10.6118/jmm.2016.22.2.76

Postmenopausal Osteoporosis Is Associated with Serum Chemerin and Irisin but Not with Apolipoprotein M Levels

Yaprak Engin-Üstün1, Emel Kıyak Çağlayan1, Ayşe Yeşim Göçmen2, Muhammed Fevzi Polat2

1Department of Obstetrics and Gynecology, Faculty of Medicine, Bozok University, Yozgat, Turkey.

2Department of Biochemistry, Faculty of Medicine, Bozok University, Yozgat, Turkey.

Address for Correspondence: Yaprak Engin-Üstün, Department of Obstetrics and Gynecology, Faculty of Medicine, Bozok University, Güzeltepe Mahallesi, Park Vadi Sitesi A4 Blok No: 97, Dikmen, Ankara, Turkey, Postal code: 06610. Tel: +05359597116, Fax: +90-312-3124931, ustunyaprak@yahoo.com

Received 6 April 2016       Revised 26 June 2016       Accepted 11 July 2016

Copyright © 2016 by The Korean Society of Menopause

(open-access):

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/).

Abstract

Objectives

The objective of this study was to describe the levels of chemerin, irisin and apolipoprotein M (apoM) in women with postmenopausal osteoporosis.

Methods

The study included 88 women with postmenopausal osteoporosis. Based on World Health Organization criteria, women with a T-score of ≤ –2.5 were defined as osteoporotic. In this case-control study, postmenopausal women with T-score > –1 were selected as controls (n = 88) and case-matched in a 1:1 ratio based on age (within 2 years) and body mass index (BMI) (within 1.0 kg/m2). ApoM, irisin and chemerin levels were determined by a commercially available enzyme-linked immunosorbent assay (ELISA) kit.

Results

There were no significant differences in age, BMI, parity, cholesterol and apoM levels between the two groups. C-reactive protein levels were significantly increased in women with osteoporosis. Serum chemerin levels (240.1 ± 46.1 vs. 261.5 ± 50.8 ng/mL) were significantly lower in the women with osteoporosis, as compared to the controls (P = 0.004). Serum irisin levels were also decreased in women with osteoporosis (0.7 ± 0.2 vs. 0.8 ± 0.2 ng/mL; P = 0.007).

Conclusion

In the present study, osteoporosis was associated with decreased levels of circulating chemerin and irisin. These findings suggested that adipokines might play a role in the pathogenesis of osteoporosis.

Keywords: Adipokines, Apolipoproteins, Osteoporosis, postmenopausal

Introduction

The pathophysiologic link between adipose tissue and bone metabolism is not entirely understood, but adipokines seem to play an important role.12 Levels of several adipokines have been found to correlate with bone mass.34
Irisin is a recently identified myokine secreted by skeletal muscle and adipose tissue.5 Serum irisin levels were found to be lower in women with previous osteoporotic fractures compared to controls.67 Chemerin, a more recently discovered adipose tissue specific adipokine, has a crucial role in adipocyte differentiation and development, as well as in glucose and lipid metabolism.8 Apolipoprotein M (apoM) has atheroprotective effects attributed to high-density lipoprotein (HDL) and has an important role in insulin and glucose metabolism.9 In the present study, we evaluated the links among serum chemerin, irisin and apoM levels in women with postmenopausal osteoporosis. Such knowledge may lead to new insights into the understanding of different cross-talks and treatment of people suffering osteoporosis.
The objective of this study is to describe the levels of chemerin, irisin and apoM in women with postmenopausal osteoporosis.

Materials and Methods

A total of 176 women who had been postmenopausal for at least 12 months and visited Bozok University Menopause Clinic for the evaluation and treatment of osteoporosis were enrolled in this cross-sectional study.
The study included 88 women with postmenopausal osteoporosis. The current analysis is a case-control study in postmenopausal women with T-score > -1 were selected as controls (n = 88) and matched on age (within 2 years), body mass index (BMI) (within 1.0 kg/m2) in a 1:1 ratio to cases. Bone mineral density (BMD) was measured using dual energy X-ray absorptiometry (DXA). Measurements included BMD of the hip (femoral neck) and lumbar spine (L1-L4) and were performed in the anteroposterior (AP) view for the lumbar spine. According to World Health Organization criteria, a T-score of ≥ -1 denotes normal bone, a T-score between -1 and -2.5 denotes osteopenia, and a T-score of ≤ -2.5 denotes osteoporosis. The BMI was calculated as weight (kg)/square height (m2).Women with systemic disorders (diabetes mellitus, rheumatoid arthritis...), who had taken drugs that could affect bone metabolism, with premature menopause (< 40 years of age) were excluded. The protocol used was approved by the Committee on Ethics of the university and funded by the university (BAP Project).
After an overnight fasting, venous blood samples were collected. All samples were obtained during the spring (March to May 2014). Within an hour of venipuncture, whole blood samples were centrifuged and separated, and serum portions were frozen at -80℃ for future analysis. ApoM, irisin and chemerin levels were determined using a commercially available enzyme-linked immunosorbent assay (ELISA) kit (BioVendor Laboratory Medicine, Brno, Czech Republic). All other parameters were measured using standard laboratory methods in the core laboratory. Limit of detection of chemerin kit is 0.1 ng/mL. The intra-assay and inter-assay coefficient of variation (CV) were less than 7%. For irisin, the lowest level of irisin that can be detected by the assay is 1 ng/mL. Intra-assay CV (%) was 4.86 to 6.75 and inter-assay CV (%) was 6.2 to 9.66. The lowest level of apoM that can be detected by this assay is 0.07 ng/mL. Intra-assay CV (%) was 4.90 to 5.22 and inter-assay CV (%) was 5.70 to 5.80.
All analyses were conducted using SPSS Windows version 15.0 software (SPSS Inc., Chicago, IL, USA). We conducted a power analysis according to the results of our pilot study, and we determined suitable sample size as 60 patients (α = 0.05, β = 0.80 and effect size d = 0.66). Continuous variables were expressed as the mean ± standard deviation (SD). The normality of the distribution was evaluated with the Kolmogorov-Smirnov test. Parameter comparisons were performed with Student's t-test and the Mann-Whitney U test. The correlation between variables was assessed with Pearson's and Spearman's correlation tests. P value of < 0.05 was considered to be statistically significant.

Results

The results from the 88 patients diagnosed with osteoporosis and the 88 patients who consisted of the control group were depicted in Table 1. There were no significant differences in age, BMI, parity, cholesterol and apoM levels between the two groups.
C-reactive protein levels were significantly increased in women with osteoporosis. Serum chemerin levels (240.1 ± 46.1 vs. 261.5 ± 50.8 ng/mL) were significantly lower in the women with osteoporosis compared to the controls (Table 1). In contrast serum irisin levels were also decreased in women with osteoporosis (0.7 ± 0.2 vs. 0.8 ± 0.2 ng/mL; P = 0.007).
We found a significant negative correlation between chemerin and irisin levels (r = -0.962, P = 0.0001).

Discussion

In the present study, serum chemerin and irisin concentrations have been shown to be decreased in patients with osteoporosis. Irisin is a myokine with a possible protective effect on metabolic disorders. Similar to our results, serum irisin concentrations have also been shown to be decreased in patients with osteoporosis.67 Zhang et al.8 revealed that irisin increased bone trabecular density and cortical thickness in mice by activating osteoblasts. Irisin also induces osteoblast differentiation.9
Chemerin is synthesized by the enlarged adipose tissue and released into the blood. Since the discovery of chemerin, there are numerous reports on the effects of chemerin which plays a role in the development of obesity and metabolic syndrome. Chemerin also induces insulin resistance.10 The mechanisms that regulate the serum levels of chemerin in postmenopausal women with osteoporosis are not known. There aren't many published reports about its role in osteogenesis and osteoclastogenesis. In contrast to our results, in a recent study, He et al.11 studied -for the first time- chemerin levels in patients with osteoporosis and found a higher level of serum chemerin. The study population is completely different from ours including men. The decrease of chemerin levels in osteoporosis found in our study is interesting and difficult to explain.
On the other hand, plasma apoM levels are found to be reduced in type II diabetes mellitus patients compared with controls.12 Luegmayr et al.13 revealed that osteoclasts depend on lipoproteins to modulate cellular cholesterol levels. In the present study, there was no significant difference in apoM levels between the two groups.
The strengths of this study are that participants were recruited from consecutive patients; standardized institutional methods were used for collecting self-reported data, and blood samples.
In the present study, osteoporosis is found to be associated with decreased circulating chemerin and irisin. The study of He et al.11 and the present one revealed that chemerin might play a role in the pathogenesis of osteoporosis. Further studies are required to find out the cross-talk between adipokines and bone.

Figures and Tables

Table 1

Characteristics of the two groups

jmm-22-76-i001

HDL: high-density lipoprotein, LDL: low-density lipoprotein, TG: triglyceride, CRP: C-reactive protein, ApoM: apolipoprotein M

Notes

Conflict of Interest No potential conflict of interest relevant to this article was reported.

This manuscript was presented at the 22nd World Congress on Controversies in Obstetrics, Gynecology & Infertility (COGI) to be held in Budapest, Hungary from 17 to 20 September 2015 as a poster.

References

1. Upadhyay J, Farr OM, Mantzoros CS. The role of leptin in regulating bone metabolism. Metabolism. 2015; 64:105–113.
2. Scotece M, Conde J, Abella V, López V, Pino J, Lago F, et al. Bone metabolism and adipokines: are there perspectives for bone diseases drug discovery? Expert Opin Drug Discov. 2014; 9:945–957.
3. Biver E, Salliot C, Combescure C, Gossec L, Hardouin P, Legroux-Gerot I, et al. Influence of adipokines and ghrelin on bone mineral density and fracture risk: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011; 96:2703–2713.
4. Tsuji K, Maeda T, Kawane T, Matsunuma A, Horiuchi N. Leptin stimulates fibroblast growth factor 23 expression in bone and suppresses renal 1alpha,25-dihydroxyvitamin D3 synthesis in leptin-deficient mice. J Bone Miner Res. 2010; 25:1711–1723.
5. Arias-Loste MT, Ranchal I, Romero-Gómez M, Crespo J. Irisin, a link among fatty liver disease, physical inactivity and insulin resistance. Int J Mol Sci. 2014; 15:23163–23178.
6. Anastasilakis AD, Polyzos SA, Makras P, Gkiomisi A, Bisbinas I, Katsarou A, et al. Circulating irisin is associated with osteoporotic fractures in postmenopausal women with low bone mass but is not affected by either teriparatide or denosumab treatment for 3 months. Osteoporos Int. 2014; 25:1633–1642.
7. Palermo A, Strollo R, Maddaloni E, Tuccinardi D, D'Onofrio L, Briganti SI, et al. Irisin is associated with osteoporotic fractures independently of bone mineral density, body composition or daily physical activity. Clin Endocrinol (Oxf). 2015; 82:615–619.
8. Zhang J, Cheng J, Tu Q, Chen J. Effects of irisin on bone metabolism and its signal mechanism. J Bone Miner Res. 2013; 28:Suppl 1. SA0185.
9. Colaianni G, Cuscito C, Mongelli T, Oranger A, Mori G, Brunetti G, et al. Irisin enhances osteoblast differentiation in vitro. Int J Endocrinol. 2014; 2014:902186.
10. Bozaoglu K, Bolton K, McMillan J, Zimmet P, Jowett J, Collier G, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology. 2007; 148:4687–4694.
11. He J, Li JC, Xie H, Xu ZH, Sun YW, Shan Q. Serum chemerin levels in relation to osteoporosis and bone mineral density: A case-control study. Dis Markers. 2015; 2015:786708.
12. Memon AA, Bennet L, Zöller B, Wang X, Palmér K, Dahlbäck B, et al. The association between apolipoprotein M and insulin resistance varies with country of birth. Nutr Metab Cardiovasc Dis. 2014; 24:1174–1180.
13. Luegmayr E, Glantschnig H, Wesolowski GA, Gentile MA, Fisher JE, Rodan GA, et al. Osteoclast formation, survival and morphology are highly dependent on exogenous cholesterol/lipoproteins. Cell Death Differ. 2004; 11:Suppl 1. S108–S118.
TOOLS
Similar articles